study of immunogenicity equivalence of a homologous third dose of covid-19 (recombinante) vaccine

Conditions: COVID-19

Summary: the purpose of this study is to evaluate the antibody response, safety and reactogenicity of a third dose covid-19 (recombinante) vaccine, 6 months after a two-dose vaccine schedule using the same vaccine in all doses.

after being informed about the study and potential risks, all participants giving written informed consent will be evaluated for eligibility criteria. at day 0, participants who meet the eligibility requirements will undergo a thorough medical evaluation and a urine pregnancy test (if applicable). previous vaccination information will be collected with the participant and checked via digital covid-19 vaccine certification from the brazilian public health national immunization program system (si-pni) ou from fundação oswaldo cruz (fiocruz) institutional occupational medicine data. according to the data collected, participants will be placed in one of two groups: 8 or 12 weeks interval between the first two vaccine doses in the vaccine schedule. eligible and consenting participants will have a blood sample collected and receive immediately after a third dose of the covid-19 (recombinante) vaccine. participants will be instructed to fill out an adverse events journal for solicited adverse events for 7 days and non-solicited adverse events for 28 days after the third dose. the research team will contact the participant remotely at least once during the first two weeks. the participant will return for a follow-up visit to the research center 28 days after the third dose, to evaluate adverse events, collect a second blood sample and undergo a thorough medical evaluation. the participant will return to the research center to collect blood samples in three more follow-up visits: 3 months, 6 months and 12 months after the third dose.

Eligibility criteria:
inclusion criteria: * employee of fundação oswaldo cruz, stationed in manguinhos campus, in rio de janeiro. * previous two-dose vaccine schedule with covid-19 (recombinante) in both doses, with an interval of8 or 12 weeks between doses. * a 6-month interval (5 to 7 month window) between the second and the third dose of covid-19 (recombinante) vaccine. * availability to participate during the entire study, and ability to follow study protocol strictly. * consent to supply personal contact information, such as telephone numbers, address and other information so the research team may contact the participant (for example, in case the participant fails to attend a scheduled visit without previous notice) * ability to understand and sign the volunteered and informed consent form, and ability to fill in the adverse events journal at home, according to the evaluation of the principal investigator ou delegated research team members. * understanding the impossibility of participating in another clinical trial while participating in this clinical trial. exclusion criteria: * receiving another covid-19 vaccine after inclusion in the study * receiving any vaccine 28 days after administration of a third dose of covid-19 (recombinante) vaccine. * refusal to sign the voluntary and informed consent form or refusal to permit collection of blood samples before the third dose of the covid-19 (recombinante) vaccine. * receiving any other vaccine 28 days before the inclusion in the study * previous vaccine schedule with other covid-19 vaccines, in the first and/or second dose. * covid-19 disease confirmed by rt-pcr (real time polymerase chain reaction) up to 28 days before inclusion in the study. * covid-19 symptoms up to 10 days before the inclusion in the study. * fever (axillary temperature above 37,8 º c / 100,04 °f) 72 hours before vaccination in the study. * contraindications to the covid-19 (recombinante) vaccine - fiocruz/astrazeneca * use of immunosuppressive medication, such as systemic corticosteroids or chemotherapy, or immunosuppressive diseases. we will consider as immunosuppressive doses of systemic corticosteroids daily doses of prednisone of 10mg or more, for more than 14 days. * incapacitating mental illness * any discoveries made by the principal investigator that would enhance the risk of an adverse result following the participation in the study, or that in some other way justifies exclusion from the study.